New study quantifies impact of monthly cost sharing caps on Part D beneficiaries
West Health commissioned a study by the actuarial firm Milliman to estimate changes in spending for insulin by various parties under several different policy proposals, including the changes proposed in the Build Back Better Act. The full methodology from Milliman's analysis is included in the report below.
Milliman's estimates for the Medicare Part D population are based on plan year 2025 utilizing the defined standard Medicare Part D benefit. Under the Medicare Part D benefit, certain low-income beneficiaries have subsidized copayments. Milliman separately analyzed the impact of policy proposals on insulin users who do not receive these subsidized copayments as well as for all beneficiaries who use insulin, including those with subsidized copayments.